<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04260893</url>
  </required_header>
  <id_info>
    <org_study_id>CLN 0734</org_study_id>
    <nct_id>NCT04260893</nct_id>
  </id_info>
  <brief_title>Prospective Study To Assess The Safety And Effectiveness Of Tixel Treatment On Dry Eye Symptoms In Asian Patients</brief_title>
  <acronym>DED</acronym>
  <official_title>A Prospective Study Assessing The Impact Of Tixel Treatment On Dry Eye Symptoms And Signs In Asian Patients With Dry Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novoxel Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novoxel Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot study where effect of standard Tixel treatment as used for periorbital wrinkles would
      be assessed on Dry Eye Disease symptoms and signs in Asian Patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety Assessment will be asses via AE/SAE reporting and Impact Assessment of the effect of
      the treatment on dry eye symptoms and signs through multiple
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All participants will undergo three sessions of treatments with the Investigation devise</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SAFETY, number of AEs</measure>
    <time_frame>8 months</time_frame>
    <description>Any safety related event during the study will be recorded and analysed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NIBUT in Seconds</measure>
    <time_frame>8 months</time_frame>
    <description>Non-Invasive Break Up Time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Surface Disease Index Questionnaire</measure>
    <time_frame>8 months</time_frame>
    <description>OSDI Score; 12 Questions; answers between 0-4; Total calculated. Higher score means worst Dry Eye Symptomes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Topography mm D</measure>
    <time_frame>8 months</time_frame>
    <description>Topography with K readings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Staining; Total Ocular Staining Score</measure>
    <time_frame>8 months</time_frame>
    <description>Corneal staining fluorescein and conjunctival/lid margin staining lissamine green</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osmolarity mOsml/L</measure>
    <time_frame>8 months</time_frame>
    <description>Osmolarity test with TearLab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slit Lamp Exam; Normal, Abnormal</measure>
    <time_frame>8 months</time_frame>
    <description>Multiple Slit Lamp tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Meibography %</measure>
    <time_frame>8 months</time_frame>
    <description>Calculate Meibography using IDRA device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Meniscus Height mm</measure>
    <time_frame>8 months</time_frame>
    <description>Tear Meniscus Height using IDRA device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lid Wiper Epitheliopathy</measure>
    <time_frame>8 months</time_frame>
    <description>Lid Wiper Epitheliopathy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Tixel Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 Tixel treatment sessions, 2 weeks apart follow by 3 Follow up sessions</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tixel</intervention_name>
    <description>Peri-Orbital fractional treatment on the Eye-Lid to assess the effect on Dry Eye symptoms</description>
    <arm_group_label>Tixel Treatment</arm_group_label>
    <other_name>Fractional</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥ 18 years.

          2. OSDI score of at least 23.

          3. Noninvasive Tear film break up time (NIKBUT) ≤ 10 seconds.

          4. No other eye or skin or immune problems.

          5. Willing and able to provide written informed consent.

          6. Willing to participate in all study activities and follow study instructions.

        Exclusion Criteria:

          1. Pregnancy and/or breastfeeding.

          2. Lesions in the periorbital area.

          3. Acute severe blepharitis.

          4. Acute conjunctivitis.

          5. Concomitant anterior eye disease.

          6. Has undergone outdoor/sunbed tanning during the last 4 weeks.

          7. Is unwilling to follow the Tixel aftercare instructions after each of the three Tixel
             treatments.

          8. Active Herpes Simplex or tendency for Herpes Simplex in the periorbital area (meaning
             the subject has had the condition previously).

          9. Current skin cancer, malignant sites and/or advanced premalignant lesions or moles in
             the treatment area.

         10. An impaired immune system condition or use of immunosuppressive medication.

         11. Collagen disorders, keloid formation and/or abnormal wound healing.

         12. Previous invasive/ablative procedures in the areas to be treated within 3 months prior
             to initial treatment or plans for such treatment during the course of the Tixel
             treatments, or before complete healing of the treatments has occurred.

         13. Has taken any medications (including via topical application), herbal treatment (oral
             or topic), food supplements or vitamins, which may cause fragile skin or impaired skin
             healing during the last 3 months.

         14. Has used oral Isotretinoin (Accutane® or Roaccutan®) within 3 months prior to
             treatment.

         15. History of bleeding coagulopathies or use of anticoagulants.

         16. Tattoos or permanent makeup in the areas to be treated.

         17. Burned skin, blistered skin, irritated skin, or sensitive skin in any of the areas to
             be treated.

         18. Thread lifting of the area to be treated in the last 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sunil Shah, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Puthasastra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mukesh Taneja, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Puthasastra</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sharon Naim, B.sc</last_name>
    <phone>00972545500152</phone>
    <email>sharon@novoxel.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ronen Shavit, M.sc</last_name>
    <phone>00972522420798</phone>
    <email>ronen@novoxel.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Khmer Sight Foundation Hospital</name>
      <address>
        <city>Phnom Penh</city>
        <country>Cambodia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil Shah, MD</last_name>
      <email>profsunilshah@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Mukesh Taneja, MD</last_name>
      <email>mukeshtaneja@yahoo.co.in</email>
    </contact_backup>
    <investigator>
      <last_name>Mukesh Taneja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Cambodia</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

